Appili Therapeutics Inc.

APLI

CA03783R1073

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 12:59:22 2024-04-30 pm EDT			5-day change	1st Jan Change
0.035 ^CAD	-12.50%		-12.50%	-.--%

Apr. 26	Appili Therapeutics Inc. announced that it has received CAD 0.3 million in funding	CI
Apr. 02	Appili Therapeutics To be Acquired by Aditxt, Inc.	MT

Appili Therapeutics Inc. Announces Demise of Rochelle Stenzler, as the Director of the Company

October 25, 2023 at 07:49 am EDT

Appili Therapeutics Inc. announced that one of its Directors, Rochelle Stenzler, has passed away. The Company plans on seeking a new independent Director to join its Board in the coming months.

Latest news about Appili Therapeutics Inc.

Appili Therapeutics Inc. announced that it has received CAD 0.3 million in funding	Apr. 25	CI
Appili Therapeutics To be Acquired by Aditxt, Inc.	Apr. 02	MT
Adivir, Inc. entered into a definitive agreement to acquire Appili Therapeutics Inc. for $6.7 million.	Apr. 01	CI
Appili Therapeutics Notes Researchers Publish Manuscript on Prevention and Emergency Response to Tularemia Outbreaks	Mar. 12	MT
Appili Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 12	CI
Appili Therapeutics Says Patent Issued For Biodefence Vaccine Candidate ATI-1701, Provides Update on Bridge Loan	Dec. 15	MT
Appili Therapeutics Brief: Announcing Issuance of Patent for ATI-1701 Biodefense Vaccine Candidate to Protect Against Tularemia and Providing Update on Bridge Loan	Dec. 15	MT
Appili Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 14	CI
Appili Therapeutics Inc. Appoints Prakash Gowd to its Board of Directors	Nov. 13	CI
Appili Therapeutics Q2 Net Loss and Comprehensive Loss Narrows Vs a Year Ago	Nov. 13	MT
Appili Therapeutics Brief: As of September 30, 2023, Co had cash of $0.4 million, compared to $2.5 million on March 31, 2023.	Nov. 13	MT
Appili Therapeutics Brief: Net loss and comprehensive loss of $1.0 million or $0.01 loss per share for the Three months ended September 30, 2023	Nov. 13	MT
Appili Therapeutics' Biodefense Vaccine Candidate ATI-1701 Awarded Additional Funding From U.S. Air Force Academy	23-10-25	MT
Appili Therapeutics Inc. Secures Commitment for Second Stage of Funding for ATI-1701 from U.S. Air Force Academy	23-10-25	CI
Appili Therapeutics Inc. Announces Funding from Defense Threat Reduction Agency for Its Biodefense Vaccine Candidate ATI-1701	23-10-25	CI
Appili Therapeutics Inc. Announces Demise of Rochelle Stenzler, as the Director of the Company	23-10-25	CI
Appili Therapeutics Provides Corporate Update	23-09-28	MT
Appili Therapeutics Presenting at 10th International Tularemia Conference	23-09-27	MT
Materials stocks drag TSX to one-month low	23-09-25	RE
Appili Therapeutics Announces U.S. FDA Approval of Likmez (ATI-1501) Metronidazole Oral Suspension	23-09-25	MT
Appili Therapeutics' Licensing Partner Gets FDA Approval for Metronidazole Oral Suspension	23-09-25	DJ
Appili Therapeutics Announces U.S. FDA Approval of Likmez (ATI-1501) Metronidazole Oral Suspension	23-09-25	CI
Appili gets US FDA approval for oral antibiotic solution	23-09-25	RE
Appili Therapeutics Brief: Announcing U.S. FDA Approval of LIKMEZ (ATI-1501) Metronidazole Oral Suspension	23-09-25	MT
Appili Therapeutics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-11	CI

Chart Appili Therapeutics Inc.

Duration

Period

More charts

Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. The Companyâs anti-infective product development portfolio includes three programs, including ATI-1701, ATI-1801 and ATI-1501. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin that affects hundreds of thousands of people around the world annually. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole.

Sector

Biotechnology & Medical Research

Calendar

2024-06-25 - Q4 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
APPILI THERAPEUTICS INC.	-.--%	3.09M
VERTEX PHARMACEUTICALS INCORPORATED	-3.46%	102B
REGENERON PHARMACEUTICALS, INC.	+1.41%	96.09B
ARGENX SE	+2.13%	22.28B
BIONTECH SE	-15.84%	21.4B
GENMAB A/S	-9.21%	18.14B
WUXI APPTEC CO., LTD.	-39.98%	17.02B
BEIGENE, LTD.	-14.65%	16.09B
NEUROCRINE BIOSCIENCES, INC.	+4.39%	13.83B
SAREPTA THERAPEUTICS, INC.	+31.35%	11.97B

Bio Therapeutic Drugs